Hematology Frontier

Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences delivered a compelling presentation on treating severe aplastic anemia. In an interview with Hematology Frontier, Prof. Zhang shared insights into managing refractory aplastic anemia and the latest treatment advancements.

On November 15–16, 2024, the "Annual Meeting of the Hematology Committee of the Chinese Medical Education Association—Great Wall Hematology Forum" was successfully held in Beijing. This conference brought together leading experts in hematology to discuss advancements in the diagnosis and treatment of hematological diseases, delve into the latest research findings, and explore the future direction of the field. Hematology Frontier had the honor of interviewing Professor Wenming Chen, Chair of the Hematology Committee and Director of the Hematology Department at Beijing Chaoyang Hospital, who shared highlights of the forum, significant achievements in China’s hematology research, and his insights into nurturing young scholars.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy (CTI) Conference was held in Hangzhou, China. Jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Asian Cellular Therapy Organization (ACTO), the Zhejiang Immunological Society, and Cell Research, this grand event was supported by The First Affiliated Hospital of Zhejiang University and Liangzhu Laboratory as host institutions. Oncology Frontier – Hematology Frontier conducted an in-depth interview with the conference chair, Dr. He Huang from The First Affiliated Hospital of Zhejiang University, to gain insight into the latest progress and future trends in the field of cell and immunotherapy.

From October 18 to 20, 2024, the “2024 Jiangsu Provincial Association of Hematology Physicians Annual Meeting,” hosted by the Jiangsu Provincial Association of Hematology Physicians and organized by Taizhou People's Hospital and the First Affiliated Hospital of Nanjing Medical University, took place in Taizhou, Jiangsu. This event focused on standardized diagnosis and treatment of hematological diseases, providing a high-level academic exchange platform for professionals in hematology. We invited Dr. Wenyu Shi, the executive chairman from Affiliated Hospital of Nantong University, to share his insights with Hematology Frontier.

On October 19, 2024, the 8th Asian Myeloma Network (AMN) Summit was held in Seoul, South Korea. At this event, the International Myeloma Foundation (IMF) hosted the AMN Awards Ceremony. Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, received the AMN Distinguished Achievement Award, recognizing his significant contributions to the field of multiple myeloma (MM) and China’s progress in this field. Following the ceremony, Hematology Frontier had the privilege of interviewing Professor Chen. He shared his thoughts on this award, the development of the AMN, and his insights and outlook on the current and future treatment landscape for MM.

The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. As the world’s largest and most comprehensive international academic conference in hematology, ASH attracts thousands of experts and scholars from around the globe each year, who come to share cutting-edge developments and breakthrough clinical data. At this year’s conference, Prof. Xiaohui Zhang’s team from the Department of Hematology, Peking University People’s Hospital, and the Institute of Hematology, Peking University, will showcase an impressive total of 11 studies, including three selected for oral presentations, underscoring China’s outstanding achievements in hematology research. This preview highlights these three oral presentations, inviting readers to follow the presentation schedules and learn more about the fascinating details and stories behind these impactful studies.

The latest 2024 NCCN guidelines for Acute Myeloid Leukemia (AML) have been published, presenting significant revisions compared to the 2023, Version 6 update. The new edition brings substantial updates in areas such as intensive induction therapy for AML, post-induction follow-up and reinduction therapy, consolidation, and maintenance treatments.

The 9th International Forum on Stem Cells (IFSC) in 2024 focuses on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers in scientific discoveries and technological advancements. During the conference, "Hematology Frontier" specially invited Dr. Daniel G.Tenen, Director of the Cancer Science Institute of Singapore, to share the potential and future trends in the field of cancer treatment.

The 9th International Forum on Stem Cells (IFSC) in 2024 focuses on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers of scientific discoveries and technological advancements. During the conference, "Hematology Frontier" specially invited Dr. Simón Méndez-Ferrer from the Cambridge Stem Cell Institute to share key pathways for improving the treatment of myeloid malignant tumors from the perspective of microenvironmental regulation.

The 9th International Forum on Stem Cells (IFSC) in 2024 focused on basic stem cell research, regenerative medicine, cell therapy, and the application of clinical research guidelines, gathering experts and scholars from around the world to discuss the latest frontiers of scientific discoveries and technological advancements. During the conference, "Hematology Frontier" specially invited Dr. Rafael Bejar from UC San Diego Health to share his exploration in the field of clonal hematopoiesis, from biological phenomena to clinical challenges.